Perspective Therapeutics has advanced its targeted alpha therapy pipeline with key milestones in clinical dose escalation, notably completing dose-limiting toxicity assessments at higher activity levels of its Lead-212 drug candidates. Concurrently, the company is expanding proprietary radiopharmaceutical manufacturing capabilities to secure supply chain reliability crucial for clinical and potential commercial stages. Its theranostic strategy, marrying diagnostic imaging with therapeutic targeting, remains a core competitive differentiator supported by orphan drug designations. Financially, a robust cash position backed by a $175 million 2026 equity raise sustains R&D investment amid ongoing operating losses.